Michel Barrois

3.0k total citations
53 papers, 2.3k citations indexed

About

Michel Barrois is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Michel Barrois has authored 53 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Michel Barrois's work include Cancer-related Molecular Pathways (12 papers), Neuroblastoma Research and Treatments (11 papers) and Cancer, Hypoxia, and Metabolism (8 papers). Michel Barrois is often cited by papers focused on Cancer-related Molecular Pathways (12 papers), Neuroblastoma Research and Treatments (11 papers) and Cancer, Hypoxia, and Metabolism (8 papers). Michel Barrois collaborates with scholars based in France, United States and Switzerland. Michel Barrois's co-authors include G Riou, Sétha Douc‐Rasy, Brigitte Bressac–de Paillerets, Pierre Duvillard, J.C. Ahomadegbe, Sandy Fogel, Francis Galibert, Agnès Chompret, Gilbert Lenoir and M. Spielmann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michel Barrois

53 papers receiving 2.2k citations

Peers

Michel Barrois

ONCOL

GENET

EPIDE

Go Yamamoto Japan

Yoshio Endo Japan

Joost J. Oudejans Netherlands

Shigeo Horiike Japan

Lee D. Cranmer United States

M Boiocchi Italy

Henry F. Sears United States

Il‐mi Okazaki Japan

Andreas Petzer Austria

Richard J. Bende Netherlands

Go Yamamoto Japan

Michel Barrois

1.2k ×1.0

645 ×0.7

ONCOL

268 ×0.6

GENET

295 ×0.7

276 ×0.7

EPIDE

Citations per year, relative to Michel Barrois Michel Barrois (= 1×) peers Go Yamamoto

Countries citing papers authored by Michel Barrois

Since Specialization

Citations

This map shows the geographic impact of Michel Barrois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Barrois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Barrois more than expected).

Fields of papers citing papers by Michel Barrois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Barrois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Barrois. The network helps show where Michel Barrois may publish in the future.

Co-authorship network of co-authors of Michel Barrois

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Barrois. A scholar is included among the top collaborators of Michel Barrois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Barrois. Michel Barrois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barrois, Michel, Alexandre Vivanti, Jonathan Rosenblatt, et al.. (2023). Non‐invasive cell‐free DNA prenatal screening for trisomy 21 as part of primary screening strategy in twin pregnancy. Ultrasound in Obstetrics and Gynecology. 63(6). 807–814. 1 indexed citations

Ladroue, Christophe, David Hoogewijs, Sophie Gad, et al.. (2011). Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica. 97(1). 9–14. 38 indexed citations

Boige, Valérie, Jean Mendiboure, Jean‐Pierre Pignon, et al.. (2010). Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. American Journal of Clinical Oncology. 28(15). 2556–2564. 3 indexed citations

Chaudru, Valérie, Min‐Tzu Lo, Fabienne Lesueur, et al.. (2009). Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. Familial Cancer. 8(4). 371–377. 7 indexed citations

Pham, D, et al.. (2009). Functional, structural, and genetic evaluation of 20CDKN2Agerm line mutations identified in melanoma-prone families or patients. Human Mutation. 30(4). 564–574. 29 indexed citations

Monnerat, Christian, Agnès Chompret, Caroline Kannengiesser, et al.. (2007). BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Familial Cancer. 6(4). 453–461. 30 indexed citations

Geoerger, Birgit, Victor W. van Beusechem, Paule Opolon, et al.. (2005). Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. The Journal of Gene Medicine. 7(5). 584–594. 23 indexed citations

Laud, Karine, Cătălin Marian, Marie‐Françoise Avril, et al.. (2005). Comprehensive analysis of CDKN2A (p16^INK4A/p14^ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. Journal of Medical Genetics. 43(1). 39–47. 41 indexed citations

Barrois, Michel, et al.. (2004). Real‐time PCR‐based gene dosage assay for detecting BRCA1 rearrangements in breast–ovarian cancer families. Clinical Genetics. 65(2). 131–136. 40 indexed citations

10.

Lazar, Vladimir, Pierre Validire, Sophie Richon, et al.. (2002). Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. British Journal of Cancer. 86(8). 1283–1289. 21 indexed citations

11.

Douc‐Rasy, Sétha, Michel Barrois, Mourad Kaghad, et al.. (2002). ΔN-p73α Accumulates in Human Neuroblastic Tumors. American Journal Of Pathology. 160(2). 631–639. 49 indexed citations

12.

Valent, Alexander, G. Le Roux, Michel Barrois, et al.. (2002). MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. The Journal of Pathology. 198(4). 495–501. 17 indexed citations

13.

Valent, Alexander, Jean Bénard, Bernard Clausse, et al.. (2001). In Vivo Elimination of Acentric Double Minutes Containing Amplified MYCN from Neuroblastoma Tumor Cells Through the Formation of Micronuclei. American Journal Of Pathology. 158(5). 1579–1584. 61 indexed citations

14.

Raguénez, Gilda, Étienne Blanc, David Goldschneider, et al.. (2001). Vers une carte génétique fonctionnelle des neuroblastomes métastatiques pour une thérapeutique adaptée. Bulletin du Cancer. 88(3). 295–304. 1 indexed citations

15.

Riou, G, et al.. (2001). c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. International Journal of Cancer. 95(4). 266–270. 38 indexed citations

16.

Barrois, Michel, et al.. (2001). Genomic and allelic expression status of thep73 gene in human neuroblastoma. Medical and Pediatric Oncology. 36(1). 45–47. 4 indexed citations

17.

Marangoni, Elisabetta, Muriel Le Romancer, Nicolas Foray, et al.. (2000). Transfer of Ku86 RNA antisense decreases the radioresistance of human fibroblasts. Cancer Gene Therapy. 7(2). 339–346. 39 indexed citations

18.

Riou, G, et al.. (1995). The p53 and mdm‐2 genes in human testicular germ‐cell tumors. Molecular Carcinogenesis. 12(3). 124–131. 83 indexed citations

19.

Riou, G, Michel Barrois, & D-C Zhou. (1991). Expression of anionic glutathione S transferase (GSTπ) gene in carcinomas of the uterine cervix and in normal cervices. British Journal of Cancer. 63(2). 191–194. 7 indexed citations

20.

Barrois, Michel, et al.. (1988). Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.. PubMed. 3(1). 21–31. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact